These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6440588)

  • 1. Efficacy of porcine factor VIII in the management of haemophiliacs with inhibitors.
    Ciavarella N; Antoncecchi S; Ranieri P
    Br J Haematol; 1984 Dec; 58(4):641-8. PubMed ID: 6440588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.
    Brettler DB; Forsberg AD; Levine PH; Aledort LM; Hilgartner MW; Kasper CK; Lusher JM; McMillan C; Roberts H
    Arch Intern Med; 1989 Jun; 149(6):1381-5. PubMed ID: 2499293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.
    Lozier JN; Santagostino E; Kasper CK; Teitel JM; Hay CR
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):10-21. PubMed ID: 8480192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of anti-human and anti-porcine factor VIII inhibitor levels in 63 patients with severe haemophilia A. A French Multicentric Study.
    Fiks-Sigaud M; Bendelac L; Parquet A; Verroust F; Torchet MF; Berthier AM; Fressinaud E; Guerois C; Aillaud MF; Boneu B
    Vox Sang; 1993; 64(4):210-4. PubMed ID: 8517049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII.
    Kernoff PB; Thomas ND; Lilley PA; Matthews KB; Goldman E; Tuddenham EG
    Blood; 1984 Jan; 63(1):31-41. PubMed ID: 6418234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with highly purified porcine factor VIII in a patient with haemophilia A and a factor VIII inhibitor.
    Colvin BT; Ainsworth M; Buckley C
    Clin Lab Haematol; 1983; 5(1):55-9. PubMed ID: 6406130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of polyelectrolyte-fractionated porcine factor VIII in the treatment of a spontaneously acquired inhibitor to factor VIII.
    Hultin MB; Hennessey J
    Thromb Res; 1989 Jul; 55(1):51-6. PubMed ID: 2506662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII.
    Parker ET; Craddock HN; Barrow RT; Lollar P
    J Thromb Haemost; 2004 Apr; 2(4):605-11. PubMed ID: 15102015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
    Klukowska A; Zieleniewska B
    Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Porcine factor VIII provides clinical benefit to patients with high levels of inhibitors to human and porcine factor VIII.
    Gribble J; Garvey MB
    Haemophilia; 2000 Sep; 6(5):482-5. PubMed ID: 11012689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey.
    Hay CR; Lozier JN; Lee CA; Laffan M; Tradati F; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A; Teitel J; Mannucci PM; Kasper CK
    Thromb Haemost; 1996 Jan; 75(1):25-9. PubMed ID: 8713775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia].
    Windyga J; Rzymkiewicz L; Lopaciuk S
    Acta Haematol Pol; 1996; 27(1):27-31. PubMed ID: 8629440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
    Kempton CL; Abshire TC; Deveras RA; Hoots WK; Gill JC; Kessler CM; Key NS; Konkle BA; Kuriakose P; Macfarlane DE; Bergman G
    Haemophilia; 2012 Sep; 18(5):798-804. PubMed ID: 22512291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease.
    Tuddenham EG; Lane RS; Rotblat F; Johnson AJ; Snape TJ; Middleton S; Kernoff PB
    Br J Haematol; 1982 Oct; 52(2):259-67. PubMed ID: 6812613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIII inhibitor postpartum.
    Michiels JJ; Bosch LJ; van der Plas PM; Abels J
    Scand J Haematol; 1978 Feb; 20(2):97-107. PubMed ID: 305611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Poly-electrolyte fractionated porcine factor VIII in the treatment of hemophilia A].
    Ferencz T; Skopál J; Csáki C; Laczkó M; Schuler D; Borsi J
    Orv Hetil; 1993 Dec; 134(52):2873-5. PubMed ID: 8272354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
    Meili EO; Dazzi H; von Felten A
    Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of porcine factor VIII in the treatment of patients with acquired hemophilia.
    Morrison AE; Ludlam CA; Kessler C
    Blood; 1993 Mar; 81(6):1513-20. PubMed ID: 8453098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evidence behind inhibitor treatment with porcine factor VIII.
    Lee CA
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():5-8. PubMed ID: 12214138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.